Turku Biotech Raises €2.5 Million to Scale Urine-Based Cancer Test in China
AQ Biotech, a diagnostic startup based in Turku, Finland, closed €2.5 million in seed funding on September 7, a mix of equity from undisclosed private investors and research-and-development support from Business Finland. The capital will finance a geographic expansion into Hong Kong and mainland China, new hires in both regions, and a push to scale its antibody-free phage-biosensor platform for detecting cancer through urine samples.
The money arrives as AQ prepares to commercialize technology that has been years in the making. CEO and co-founder Timo Teimonen declined to name the private backers or disclose the round's valuation.
The expansion plan rests on a three-node structure. A Hong Kong holding company, AQ Biotech Global, oversees two mainland joint ventures formed this spring. AQ Biotech Nanjing, established May 8 with local partner OG Pharmaceuticals, focuses on prostate and urological cancers. AQ Biotech Chengdu, formed six days later with Sichuan Yiaijinxuan Technology, will pursue Parkinson's disease screening. The Hong Kong entity acts as what the company calls a "super-connector" between its Finnish headquarters and Chinese clinical sites.
The underlying diagnostic pairs engineered bacteriophages with a colorimetric dye that shifts color when the virus binds to disease-associated biomarkers in urine. Bacteriophages—viruses that infect bacteria—can be tailored to recognize specific molecules. Results can be read on a standard absorbance plate reader or through a smartphone app the company has developed called AQ MOBI. AQ positions the approach as an alternative to antibody-based assays, which it describes as less stable and costlier to produce at commercial scale.
Prostate cancer is the lead application. The company said its test can classify high-grade prostate tumors, specifically Grade Groups 4 and 5, from a single urine sample. AQ pointed to peer-reviewed studies published in Scientific Reports in February 2022 and scheduled for publication in Life in May 2024. Research teams in Nanjing and Shanghai have measured 737 urine samples using the sensors, accumulating more than 120,000 data points, according to a company post from August. Whether that volume translates to clinical validation at the scale needed for regulatory approval remains an open question.
The company is also developing programs for metastatic cancer detection and Parkinson's disease. The latter is a collaboration with Valtteri Kaasinen, a neurologist at Turku University Hospital.
China offers AQ something Finland cannot: patient populations large enough to generate the clinical evidence diagnostics companies need to convince regulators and payers. The Nanjing venture will work with Jiangsu Cancer Hospital, a Class 3A institution, on cohorts involving prostate and urinary-tract cancers. The Chengdu venture collaborates with West China Hospital of Sichuan University on Parkinson's screening. That project received funding approval from Business Finland under a joint China-Finland call coordinated with China's Ministry of Science and Technology, according to the company's May 14 announcement.
"Both regions give us access to world-class clinical research hospitals serving patient populations in the tens, even hundreds, of millions," Teimonen wrote in a profile published by Central Baltic.
AQ added Dongqing Wei, a professor of artificial intelligence for life sciences at Shanghai Jiao Tong University, to its board in May as a senior advisor. The company's leadership includes co-founders Janne Kulpakko, chief science officer, and Jukka Holappa, chief business officer. LinkedIn data captured September 8 showed the startup employed between 11 and 50 people. Ville Tolvanen, who joined as a shareholder in November, serves as board chair.
The startup holds patents covering prostate cancer biomarker detection in the United States, Europe, China, and Canada. One filing traces back to Aqsens Health, an earlier entity the research team operated before incorporating AQ Biotech. In April, the company hired Toni Karhu as head of biomarker discovery, Sini Huuskonen as principal scientist, and Satu Tiittanen as senior scientist and quality lead. A job posting for a Chinese-speaking application scientist appeared over the summer.
"AQ Biotech is developing and commercializing an innovative patented technology, with several potential high impact use cases on international markets," Tuomas Planman, a senior advisor on Business Finland's startup and scale-up team, said in the September 7 announcement. "Business Finland is happy to support AQ Biotech with R&D funding, alongside private investors."
The company's timeline suggests it has been building toward this moment for some time. How quickly it can turn laboratory results into a commercial diagnostic in a market as complex as China's will determine whether the seed capital was just the beginning.
